Elite Comes Through

2020 is here and it looks like $ELTP made critical changes that may lead to some big days ahead.  Big green days.  GMAN24 nailed it by posting these two comments to support the buzz.

Some thoughts from N2k

A final thought: Based on a strategic decision that totally realigned its product focus (and which cost additional shares to fund), Elite has become a well-diversified generics company. As a generics firm, the focus is on price not differentiation. SOX was an NDA and, thus, differentiated. It was a strategic anomaly and, I believe, a mistaken decision for a generics firm to make. But I forgive them the mistake because they are not attempting to escalate their financial commitment to an opioid product line that has socio-legal-political issues. Moreover, ADFs, while a grand idea, are and remain a costly drug. ICER has put out a report that indicates ADF opioids are overpriced by 40% and it is a major reason they will not gain the traction with the now cautious prescribers who do not believe their patients are at risk of abuse or diversion. Because the cost of ADF opioids is high, abuse threat low, and many of these people are on fixed incomes and sensitive to pricing, healthcare professionals will not easily prescribe ADFs.

And, there is the fact that the CNS ANDAs will be more profitable and reach a larger market.

So it is that we investors owe Nasrat and Elite a vote of thanks, respect and trust. Management is moving Elite toward success that early investors could not have imagined and it is because at a key tipping point they made a strategic decision that now finds the company with increasing revenues and on the doorstep of financial success. I am now invested in a better company than when I first began.

WeeZuhl

Yesterday was the biggest day in the history of Elite Pharmaceuticals. We have never had any product with this much upside potential. It is particularly beneficial that the company has API quota in place and is ready to ship product within a few weeks to a distributor with the name and infrastructure to immediately start gaining market share. I say this is the "next phase" for two reasons: the IR and ER Adderall products will (1) make this company profitable (E is for earnings) and (2) allow further development without further dilution.


Congratulations to all long term investors. This is what we've been waiting for. Lots of investors have found this stock along the away, but I offer special praise to those investors with the insight and patience necessary to recognize the ongoing potential despite the recurrent setbacks. And while I am praising insight and patience, let's not forget Elite management. While the future of ADF opioids is in doubt, the future of Elite Pharmaceutical is very clear. For that fact alone, I give Nasrat Hakim great credit. I believe he showed true vision and was ahead of his peers in seeing problems in the ADF market and general decline in opioid prescriptions. The timely transition to ADHD drugs was a smart choice that aligns perfectly with Elite's model of niche drugs with high barriers to entry. The team has the facilities well-prepared, and the right products are starting to line up.


The next phase will require a second shift. It's time for our factory to get busy. We've literally got a license to cook crank, so let's really start slinging that speed!

Elite Pharmaceuticals 2020 Looks Up

Trudging slowly over the pharmaceutical stock pile is not laughing matter.   So much hangs on their pipelines which dangle like a carrot as the FDA makes their methodical decisions that either propel or body slam a stock to its new dimension.

Elite has made some amazing achievements in a timely manner in 2019. 

Dec 12, 2019

Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall XR(R)

NORTHVALE, NJ / ACCESSWIRE / December 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing its own generic products, partnered generic products and proprietary abuse-deterrent opioids, today announced that it received approval from the US Food and Drug Administration (FDA) for a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules. The product is a central nervous system stimulant and is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). According to IQVIA (formerly QuintilesIMS Health) data, the branded product and its equivalents had total U.S. sales of $1.3 billion for the twelve months ending October 2019. Generic Adderall XR is jointly owned and the second product approval for our Elite and SunGen Pharma LLC ("SunGen") collaboration. Elite will manufacture and package the product on a cost-plus basis. Lannett Company, Inc. will be the exclusive U.S. distributor. "We are pleased to have received approval of this second product co-developed with our partner, SunGen," said Nasrat Hakim, President and CEO of Elite. "Launch of this product is our top priority." "We are very pleased to have another ANDA approval through our partnership with Elite and achieve a significant milestone for Sungen as we work on the launch of the recently approved generic Adderall XR®," said Dr. Jim Huang, Co-CEO of SunGen.

Higher 52 Average

Don't look now but ELTP is looking to raise her established baseline.  All this needs is the FDA to do what the company has hoped it would do for years and years.   Approve!

The Message Is Universal

SIGNS OF LIFE

ELTP Message Boards Have Traditionally Been Noisy

So what the hell is wrong with you?  Are you afraid a pussy like Lowenstein or his 2 or 3 midget followers might be right?   Ok they've been kinda right but who likes the tone and tenor?

Hard to watch as red day after the next builds and builds and the company goes dark...

Gone are the days of lively round tables and these are the days where details are just continually getting in the way.

Stay loud though, I have always had faith that Elite will have a day that we all will be proud of, but yeah I'm worn down and my modest holdings are now way down and I didn't think it'd come to this but I am worried.  I don't want ELTP to fold.  So stay loud.

5 cents? Makes NO sense!

ELTP has been at a standby and decline mode of activity over the last many months.  Investors are getting sick and tired of waiting and the haters are here, barfing their spin and in essence kicking the man laying down and bloodied from all the lack of information and positive news.

BUT there is hope ...

right?

Here is the one year chart....

and here is the last year of news released by ELTP:

6/24/2019	06:04	EDGAR	Current Report Filing (8-k)
6/21/2019	16:33	EDGAR	Annual Report (10-k)
6/14/2019	13:00	EDGAR	Notification That Annual Report Will Be Submitted Late (nt..
3/11/2019	16:04	EDGAR	Current Report Filing (8-k)
2/12/2019	06:11	EDGAR	Current Report Filing (8-k)
1/03/2019	15:58	EDGAR	Current Report Filing (8-k)
12/10/2018	16:02	EDGAR	Current Report Filing (8-k)
11/20/2018	16:08	EDGAR	Current Report Filing (8-k)
11/09/2018	17:02	EDGAR	Current Report Filing (8-k)
11/09/2018	16:38	EDGAR	Quarterly Report (10-q)
11/05/2018	16:08	EDGAR	Current Report Filing (8-k)
10/23/2018	16:22	EDGAR	Current Report Filing (8-k)
10/17/2018	17:17	EDGAR	Amended Quarterly Report (10-q/a)
9/18/2018	16:18	EDGAR	Current Report Filing (8-k)
9/06/2018	11:38	EDGAR	Confidential Treatment Order (ct Order)
8/30/2018	16:18	EDGAR	Amended Current Report Filing (8-k/a)
8/14/2018	13:21	EDGAR	Current Report Filing (8-k)
8/09/2018	16:59	EDGAR	Current Report Filing (8-k)
8/09/2018	16:36	EDGAR	Quarterly Report (10-q)
8/07/2018	16:03	EDGAR	Current Report Filing (8-k)
8/06/2018	16:17	EDGAR	Current Report Filing (8-k)

See any correlations?   No news is bad news for this company, and while you see the reporting (that's a good thing, right?) - there's no meat being given.  Nasrat has been awful in his tenure with the company and many are wishing a way for the old ELTP management.   Sure things were tighter, and loans were flying around, but there was a sense of urgency and there was progress and the investors were feeling much more part of the scene.  Look for more PRs by ELTP in upcoming months.  This price is no where near the "dollar-land" promised by Nasrat and the investors want something they can chew on.  Free advice for a company I have had my eyes on for years.
 

ELTP Conference Call Today

ELTP is swelling, the question is when the dam will give.

With a handful of haters and a swarm of newbie's to the scene, the message boards on various sites are lacking the same confidence as three or four years ago, but there is plenty of technical aspects that continues to draw enough attention for better or worse.

Today's conference call isn't going to do enough to stimulate a buying frenzy, with a disappointing $2.6 million quarter the best that can be done is to notice this is an upward trend month over month.  Of course it's not when you look at the year over year numbers, so it looks like the sticks will be pushed forward to next quarter if that's what is most important on your mind.

Now if the FDA would just relax and just grant ELTP their prize piece of their puzzle, there could be a modest eruption.  In the meanwhile, their pieces continue to approved, however slowly.   It's sometimes painful, and Nasrat has put a lot of his supporters on the defensive.  He needs to get some things going his way.

ELTP 2019

Elite Pharmaceuticals is in a position to absolutely smash through some of the sneaky shit that has an unfortunate neck squeeze on its current PPS. The value of Elite is in its pipeline. Some 41 drugs, yet we have seen nothing but red and a sorry looking chart. There are a few people who post really nasty shit against the company on the message boards, but I warned you about them years ago. It's a great feeling to check those boards after an ELTP run because those few posters are nowhere to be found. But where are runs? 2019 may be a huge year for this company, so check those boards infrequently, but keep your eyes open for news from the company and their conference calls (which never amount to much...) and with a little luck and good timing this will be a winner. Do yourself a favor and hold your position or better yet dive bomb into those super low-priced gems. They do have value, only time will tell how much value.